Liver/Biliary Disorders News

Modifying the timing of daily energy intake may improve metabolic health and restore natural circadian rhythms among patients with nonalcoholic fatty liver disease, according to a review published in Gut.

Nearly 75% of patients with end-stage liver disease in safety-net hospitals were not referred for liver transplant evaluation, mostly due to active alcohol use or insurance issues, according to data published in JAMA Network Open.

The risk for hepatic decompensation and hepatocellular carcinoma remained constant after hepatitis C virus cure among patients with advanced chronic liver disease, underscoring the need for post-HCV risk stratification in the long term.

In a Healio video exclusive, Andreas Kremer, MD, PhD, MHBA, highlights recent data on primary biliary cholangitis presented at EASL Congress, including risk factors for disease progression and seladelpar for treatment of pruritus.

The first half of 2023 has already seen landmark FDA decisions in the gastroenterology space, including multiple first-in-class therapies along with two costly rejections that highlight persistent gaps in the GI drug armory.

Failure to achieve sustained virological response and the presence of more advanced chronic liver disease were associated with mortality in patients with hepatitis C and hepatocellular carcinoma, according to a researcher at EASL Congress.

In patients with idiosyncratic drug-induced liver injury, previous history of an allergic reaction related to drugs correlated with worse clinical outcomes, including death, according to data presented at the EASL Congress.

Topline findings from the phase 3 ELATIVE trial showed that elafibranor improved cholestasis response in patients with primary biliary cholangitis, Ipsen and Genfit announced.

Xarelto improved portal hypertension complication-free survival in patients with cirrhosis and moderate liver dysfunction without an increase in major bleeding events, according to data presented at the EASL Congress.

Mycophenolate mofetil was superior to azathioprine in achieving biochemical remission in treatment-naive patients with autoimmune hepatitis who were also treated with prednisolone, according to data presented at EASL Congress.